In case, this has been missed. Phase 1 success announced in news 30 March 2020.
Study evaluated safety and pharmacokinetics of BP001 compared to Xolair in healthy volunteers.
BiosanaPharma, an Australian/Dutch biotech company, today announced the successful outcome of a comparative phase I clinical study in healthy volunteers of BP001, a biosimilar candidate to Xolair. The study was conducted in Australia, with 84 healthy male volunteers. The results of the study show that bioavailability, safety, tolerability and immunogenicity of BP001 are comparable to those of Xolair.
BP001 is produced by utilising BiosanaPharma’s innovative ‘3C process’, a fully continuous manufacturing process, cutting production costs by up to 90%. This makes BP001 the first clinical monoclonal antibody in the world to be produced with a fully continuous process, according to available market information.
This phase I study supports the further clinical development of BP001, where the next step will be a phase III study comparing BP001 to the originator in patients with allergic asthma. This study is planned to start early 2021.
(20min delay)